ScripJazz Pharmaceuticals has agreed to buy Chimerx in a deal valued at about $935m, giving the company a near-to-market drug for a rare type of cancer. The transaction announced on 5 March comes roughly a
Pink SheetHarmony Biosciences plans to accelerate Phase III development of a high-dose pitolisant formulation (pitolisant HD) in idiopathic hypersomnia (IH) after the US Food and Drug Administration turned down
Scrip“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office
ScripHarmony Biosciences plans to accelerate Phase III development of a high-dose pitolisant formulation (pitolisant HD) in idiopathic hypersomnia (IH) after the US Food and Drug Administration turned down